🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesMy dad had a heart attack and now I am terrified - will GLP-1 help? — need advice

My dad had a heart attack and now I am terrified - will GLP-1 help? — need advice

Dr.NephBHM_UK Sun, Oct 6, 2024 at 5:41 PM 15 replies 1,830 viewsPage 1 of 3
This thread is more than 20 months old. Information may be outdated. Consider searching for more recent discussions.
Dr.NephBHM_UK
Member
456
2,123
Jun 2024
Birmingham, UK
Oct 6, 2024 at 5:41 PM#1

Writing this once so I can stop repeating it across threads. It is about cardiovascular outcomes, and it is deliberately narrow — everything I am not confident about is marked as such.

What is actually established

SELECT is the trial that changed the framing of this class, because it was an outcome trial rather than a weight trial: about a 20% relative reduction in major adverse cardiovascular events in people with established cardiovascular disease and overweight or obesity, without diabetes. The effect appeared earlier than the weight-loss curve can comfortably explain, which is the basis for arguing that some of the benefit is direct — anti-inflammatory and vascular — rather than purely a consequence of weight.

The condition it depends on

The qualification that SELECT enrolled a secondary-prevention population. Extrapolating a 20% relative reduction to a healthy 35-year-old with a BMI of 31 is not what that trial showed.

The practical version

Relative versus absolute is the distinction that gets lost: a 20% relative reduction on a high baseline risk is a large absolute benefit, and the same relative figure on a low baseline risk is a small one.

What I am not sure about

The question I want answered is how much of the SELECT benefit is plausibly independent of the weight loss, and whether that distinction changes anything practical. Tell me what I have not thought of.

— Dr.NephBHM_UK · corrections welcome and will be edited into this post with credit
34 4Dr.CardioMD, EndoResFellow, PharmacoVig_BOS and 31 others
Reply Quote Save Share Report
TrialTracker_MD
Senior Member
2,345
15,678
Jan 2024
Maryland
Oct 6, 2024 at 6:15 PM#2
Dr.NephBHM_UK said:
SELECT is the trial that changed the framing of this class, because it was an outcome trial rather than a weight trial: about a 20% relative reduction…

Anti-inflammatory mechanisms of GLP-1 agonists and cardiovascular risk: beyond weight loss, GLP-1R activation directly suppresses NF-κB signaling, reduces NLRP3 inflammasome activation, and decreases monocyte/macrophage adhesion to endothelium[1].

Clinical correlates: hsCRP reduction of 30-60% (consistently seen across trials), reduced carotid intima-media thickness, and decreased coronary plaque inflammation on PET imaging.

These anti-inflammatory effects likely contribute to the cardiovascular benefit seen in SELECT — and may explain benefits beyond what weight loss alone would predict.

References:
[1] Hogan AE, et al. Diabetologia. 2014;57(4):781-784.
Last edited: Oct 6, 2024 at 11:15 PM
33 3stefan_berlin, Dr.EM_Chicago, pete_RVA and 30 others
Reply Quote Save Share Report
Dr.MetabolicMD
VIP Member
2,345
16,789
Jan 2024
Rochester, MN
Oct 6, 2024 at 6:49 PM#3
Dr.NephBHM_UK said:
SELECT is the trial that changed the framing of this class, because it was an outcome trial rather than a weight trial: about a 20% relative reduction…

Pushing back on Dr.NephBHM_UK here. The "earlier than weight loss explains" argument is weaker than this thread makes it sound. Blood pressure and inflammatory markers move fast and are downstream of early weight loss, so the mechanism is not as cleanly separable as the summaries imply.

Last edited: Oct 6, 2024 at 8:49 PM
32 2HealthEcon_DC, PedsEndoPhilly, SleepDoc_PDX and 29 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
NurseAsh_DET
Member
356
1,567
Sep 2024
Detroit, MI
Oct 6, 2024 at 7:23 PM#4
Dr.MetabolicMD said:
The "earlier than weight loss explains" argument is weaker than this thread makes it sound.

CRP reduction on cardiovascular risk — this is the lab result that excites me most:

Baseline hsCRP: 12.0 mg/L (high cardiovascular risk)
Month 6 hsCRP: 2.5 mg/L (moderate risk)
Month 12 hsCRP: 0.8 mg/L (low risk)

This level of inflammatory marker reduction is comparable to what you'd see with statin therapy. Combined with the weight loss, my 10-year ASCVD risk score dropped from 19% to 5%. My cardiologist is genuinely impressed.

31 1labquiet_amy, emily_PDX, Dr.SleepRoch and 28 others
Reply Quote Save Share Report
steph_laguna
Member
234
1,123
Nov 2024
Laguna Beach, CA
Oct 6, 2024 at 10:33 PM#5
TrialTracker_MD said:
Anti-inflammatory mechanisms of GLP-1 agonists and cardiovascular risk: beyond weight loss, GLP-1R activation directly suppresses NF-κB signaling,…

Adding a me-too, because a thread of one person's experience is not much use. The detail I would add is minor and it is already implied above.

30 0marco_milano, pam_columbus, nick_SD_fit and 27 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register